Issue
SICOT-J
Volume 6, 2020
Special Issue: "HIP and KNEE Replacement" Guest Editors: C Batailler, S Lustig, J Caton
Article Number 26
Number of page(s) 11
DOI https://doi.org/10.1051/sicotj/2020021
Published online 07 July 2020
  1. Del Pozo JL, Patel R (2009) Clinical practice. Infection associated with prosthetic joints. N Engl J Med 361, 787–794. [Google Scholar]
  2. Osmon DR, Berbari EF, Berendt AR, et al. (2013) Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56, e1–e25. [CrossRef] [PubMed] [Google Scholar]
  3. Kapadia BH, Berg RA, Daley JA, et al. (2016) Periprosthetic joint infection. Lancet 387, 386–394. [CrossRef] [PubMed] [Google Scholar]
  4. Société de Pathologie Infectieuse de Langue Française (SPILF), Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT), Groupe de Pathologie Infectieuse Pédiatrique (GPIP), et al. (2010) Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). Société de Pathologie Infectieuse de Langue Française. Med Mal Infect 40, 185–211. [CrossRef] [PubMed] [Google Scholar]
  5. Ariza J, Cobo J, Baraia-Etxaburu J, et al. (2017) Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin 35, 189–195. [CrossRef] [PubMed] [Google Scholar]
  6. Abouljoud MM, Backstein D, Battenberg A, et al. (2019) Hip and knee section, treatment, surgical technique: Proceedings of international consensus on orthopedic infections. J Arthroplasty 34, S445–S451. [CrossRef] [PubMed] [Google Scholar]
  7. Garcia-Rey E, Cruz-Pardos A, Madero R (2014) Clinical outcome following conversion of Girdlestone’s resection arthroplasty to total hip replacement: A retrospective matched case-control study. Bone Joint J 96-B, 1478–1484. [Google Scholar]
  8. Kantor GS, Osterkamp JA, Dorr LD, et al. (1986) Resection arthroplasty following infected total hip replacement arthroplasty. J Arthroplasty 1, 83–89. [CrossRef] [PubMed] [Google Scholar]
  9. Mahmoud SSS, Sukeik M, Alazzawi S, et al. (2016) Salvage procedures for management of prosthetic joint infection after hip and knee replacements. Open Orthop J 10, 600–614. [Google Scholar]
  10. Goldman AH, Clark NJ, Taunton MJ, et al. (2020) Definitive resection arthroplasty of the knee: A surprisingly viable treatment to manage intractable infection in selected patients. J Arthroplasty 35, 855–858. [CrossRef] [PubMed] [Google Scholar]
  11. Wilding CP, Cooper GA, Freeman AK, et al. (2016) Can a silver-coated arthrodesis implant provide a viable alternative to above knee amputation in the unsalvageable, infected total knee arthroplasty? J Arthroplasty 31, 2542–2547. [CrossRef] [PubMed] [Google Scholar]
  12. Ryan SP, DiLallo M, Klement MR, et al. (2019) Transfemoral amputation following total knee arthroplasty: Mortality and functional outcomes. Bone Joint J 101-B, 221–226. [Google Scholar]
  13. Lesens O, Ferry T, Forestier E, et al. (2018) Should we expand the indications for the DAIR (debridement, antibiotic therapy, and implant retention) procedure for Staphylococcus aureus prosthetic joint infections? A multicenter retrospective study. Eur J Clin Microbiol Infect Dis 37, 1949–1956. [CrossRef] [PubMed] [Google Scholar]
  14. Wouthuyzen-Bakker M, Nijman JM, Kampinga GA, et al. (2017) Efficacy of antibiotic suppressive therapy in patients with a prosthetic joint infection. J Bone Joint Infect 2, 77–83. [Google Scholar]
  15. Malahias M-A, Gu A, Harris EC, et al. (2020) The role of long-term antibiotic suppression in the management of peri-prosthetic joint infections treated with debridement, antibiotics, and implant retention: A systematic review. J Arthroplasty 35, 1154–1160. [CrossRef] [PubMed] [Google Scholar]
  16. Weston JT, Watts CD, Mabry TM, et al. (2018) Irrigation and debridement with chronic antibiotic suppression for the management of infected total knee arthroplasty: A contemporary analysis. Bone Joint J 100-B, 1471–1476. [Google Scholar]
  17. Prendki V, Zeller V, Passeron D, et al. (2014) Outcome of patients over 80 years of age on prolonged suppressive antibiotic therapy for at least 6 months for prosthetic joint infection. Int J Infect Dis 29, 184–189. [CrossRef] [PubMed] [Google Scholar]
  18. Escudero-Sanchez R, Senneville E, Digumber M, et al. (2019) Suppressive antibiotic therapy in prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect 26, 499–505, S1198743X19304926. [CrossRef] [PubMed] [Google Scholar]
  19. Segreti J, Nelson JA, Trenholme GM (1998) Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis 27, 711–713. [CrossRef] [PubMed] [Google Scholar]
  20. Sandiford NA, Hutt JR, Kendoff DO, et al. (2020) Prolonged suppressive antibiotic therapy is successful in the management of prosthetic joint infection. Eur J Orthop Surg Traumatol 30, 313–321. [CrossRef] [PubMed] [Google Scholar]
  21. Pradier M, Robineau O, Boucher A, et al. (2018) Suppressive antibiotic therapy with oral tetracyclines for prosthetic joint infections: Aretrospective study of 78 patients. Infection 46, 39–47. [Google Scholar]
  22. Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. N Engl J Med 351, 1645–1654. [Google Scholar]
  23. Metsemakers W-J, Morgenstern M, Senneville E, et al. (2019) General treatment principles for fracture-related infection: Recommendations from an international expert group. Arch Orthop Trauma Surg, https://doi.org/10.1007/s00402-019-03287-4. [Google Scholar]
  24. Herry Y, Reynaud O, Ferry T, et al. (2017) Intercalary diaphyseal endoprosthetic reconstruction for tibial septic non-union in an elderly patient: A case report. Orthop Traumatol Surg Res 103, 1217–1220. [Google Scholar]
  25. Grammatico-Guillon L, Baron S, Gettner S, et al. (2012) Bone and joint infections in hospitalized patients in France, 2008: Clinical and economic outcomes. J Hosp Infect 82, 40–48. [Google Scholar]
  26. Parvizi J, Pawasarat IM, Azzam KA, et al. (2010) Periprosthetic joint infection: The economic impact of methicillin-resistant infections. J Arthroplasty 25, 103–107. [CrossRef] [PubMed] [Google Scholar]
  27. Peel TN, Cheng AC, Lorenzo YP, et al. (2013) Factors influencing the cost of prosthetic joint infection treatment. J Hosp Infect 85, 213–219. [Google Scholar]
  28. Kurtz SM, Lau E, Watson H, et al. (2012) Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 27, 61–65.e1. [CrossRef] [PubMed] [Google Scholar]
  29. Ferry T, Seng P, Mainard D, et al. (2019) The CRIOAc healthcare network in France: A nationwide Health Ministry program to improve the management of bone and joint infection. Orthop Traumatol Surg Res 105, 185–190. [Google Scholar]
  30. Josse J, Valour F, Maali Y, et al. (2019) Interaction between staphylococcal biofilm and bone: How does the presence of biofilm promote prosthesis loosening? Front Microbiol 10, 1602. [CrossRef] [PubMed] [Google Scholar]
  31. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: A common cause of persistent infections. Science 284, 1318–1322. [Google Scholar]
  32. McConoughey SJ, Howlin R, Granger JF, et al. (2014) Biofilms in periprosthetic orthopedic infections. Future Microbiol 9, 987–1007. [CrossRef] [PubMed] [Google Scholar]
  33. Malhotra R, Dhawan B, Garg B, et al. (2019) A comparison of bacterial adhesion and biofilm formation on commonly used orthopaedic metal implant materials: An in vitro study. Indian J Orthop 53, 148–153. [CrossRef] [PubMed] [Google Scholar]
  34. Byren I, Bejon P, Atkins BL, et al. (2009) One hundred and twelve infected arthroplasties treated with “DAIR” (debridement, antibiotics and implant retention): Antibiotic duration and outcome. J Antimicrob Chemother 63, 1264–1271. [CrossRef] [PubMed] [Google Scholar]
  35. Simons MJ, Amin NH, Scuderi GR (2017) Acute wound complications after total knee arthroplasty: prevention and management. J Am Acad Orthop Surg 25, 547–555. [CrossRef] [PubMed] [Google Scholar]
  36. Veber M, Vaz G, Braye F, et al. (2011) Anatomical study of the medial gastrocnemius muscle flap: A quantitative assessment of the arc of rotation. Plast Reconstr Surg 128, 181–187. [Google Scholar]
  37. Economides JM, DeFazio MV, Golshani K, et al. (2017) Systematic review and comparative meta-analysis of outcomes following pedicled muscle versus fasciocutaneous flap coverage for complex periprosthetic wounds in patients with total knee arthroplasty. Arch Plast Surg 44, 124–135. [CrossRef] [PubMed] [Google Scholar]
  38. Waldman BJ, Hostin E, Mont MA, Hungerford DS (2000) Infected total knee arthroplasty treated by arthroscopic irrigation and débridement. J Arthroplasty 15, 430–436. [CrossRef] [PubMed] [Google Scholar]
  39. Pouderoux C, Becker A, Goutelle S, et al. (2019) Subcutaneous suppressive antibiotic therapy for bone and joint infections: Safety and outcome in a cohort of 10 patients. J Antimicrob Chemother 74, 2060–2064. [CrossRef] [PubMed] [Google Scholar]
  40. Goutelle S, Valour F, Gagnieu M-C, et al. (2018) Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. J Antimicrob Chemother 73, 987–994. [CrossRef] [PubMed] [Google Scholar]
  41. Ferry T, Kolenda C, Gustave C-A, et al. (2018) Phage therapy in bone and joint infection: History, scientific basis, feasibility and perspectives in France. Virologie 24, 4–11. [Google Scholar]
  42. Patey O, McCallin S, Mazure H, et al. (2018) Clinical indications and compassionate use of phage therapy: Personal experience and literature review with a focus on osteoarticular infections. Viruses 11, 18. [Google Scholar]
  43. Tkhilaishvili T, Winkler T, Müller M, et al. (2019) Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 64. https://doi.org/10.1128/AAC.00924-19. [Google Scholar]
  44. Djebara S, Maussen C, De Vos D, et al. (2019) Processing phage therapy requests in a Brussels military hospital: Lessons identified. Viruses 11. https://doi.org/10.3390/v11030265. [Google Scholar]
  45. Onsea J, Soentjens P, Djebara S, et al. (2019) Bacteriophage application for difficult-to-treat musculoskeletal infections: Development of a standardized multidisciplinary treatment protocol. Viruses 11. https://doi.org/10.3390/v11100891. [Google Scholar]
  46. Jault P, Leclerc T, Jennes S, et al. (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 19, 35–45. [CrossRef] [PubMed] [Google Scholar]
  47. Kolenda C, Josse J, Medina M, et al. (2020) Evaluation of the activity of a combination of three bacteriophages alone or in association with antibiotics on Staphylococcus aureus embedded in biofilm or internalized in osteoblasts. Antimicrob Agents Chemother 64. https://doi.org/10.1128/AAC.02231-19. [Google Scholar]
  48. Chaudhry WN, Concepción-Acevedo J, Park T, et al. (2017) Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One 12, e0168615. [CrossRef] [PubMed] [Google Scholar]
  49. Ferry T, Leboucher G, Fevre C, et al. (2018) Salvage debridement, antibiotics and implant retention (“DAIR”) with local injection of a selected cocktail of bacteriophages: Is it an option for an elderly patient with relapsing Staphylococcus aureus prosthetic-joint infection? Open Forum Infect Dis 5, ofy269. [CrossRef] [PubMed] [Google Scholar]
  50. Fischetti VA (2018) Development of phage lysins as novel therapeutics: A historical perspective. Viruses 10. https://doi.org/10.3390/v10060310. [CrossRef] [PubMed] [Google Scholar]
  51. Schuch R, Khan BK, Raz A, et al. (2017) Bacteriophage lysin CF-301, a potent antistaphylococcal biofilm agent. Antimicrob Agents Chemother 61, e02666–16. [CrossRef] [PubMed] [Google Scholar]
  52. Fowler VG, Das AF, Lipka J, et al. (2019) Exebacase (Lysin CF-301) improved clinical responder rates in methicillin resistant Staphylococcus aureus bacteremia including endocarditis compared to standard of care antibiotics alone in a first-in patient phase 2 study. In: European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam. Abstract L0012. [Google Scholar]
  53. Oh JT, Cassino C, Schuch R (2019) Postantibiotic and sub-mic effects of exebacase (Lysin CF-301) enhance antimicrobial activity against Staphylococcus aureus. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.02616-18. [Google Scholar]
  54. Chen M, Nafziger AN, Drusano GL, et al. (2006) Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 50, 1222–1227. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.